Votrient Pazopanib – 200 mg, 400 mg Tablets

At a Glance

Generic Name: Pazopanib

Brand Name: Votrient

Strength & Pack Size: 200 mg tablets (1 pack / 30 tabs); 400 mg tablets (1 pack / 30 tabs or 1 pack / 60 tabs)

Dosage Form & Route: Oral film-coated tablets taken by mouth, usually once daily

Therapeutic Class: Multitargeted tyrosine kinase inhibitor (TKI), anti-angiogenic targeted therapy

Primary Indications: Advanced or metastatic renal cell carcinoma (RCC) and selected advanced soft tissue sarcomas

Typical Use in Therapy: First-line or subsequent-line systemic treatment under specialist oncology supervision

Mode of Action: Inhibits VEGFR, PDGFR and related tyrosine kinases to reduce tumour blood supply and growth signalling

Key Benefits: Oral targeted option that allows carefully monitored treatment at home for eligible patients

Precautions: Hepatotoxicity, hypertension, QT prolongation, bleeding risk and drug interactions require close monitoring

Storage: Store in the original pack below 30 °C, protected from moisture and out of children’s reach

Product Description

Votrient contains pazopanib, an oral multikinase tyrosine kinase inhibitor used as a targeted therapy in advanced or metastatic renal cell carcinoma (RCC) and in certain advanced soft tissue sarcomas. Unlike traditional intravenous chemotherapy, Votrient pazopanib tablets are taken by mouth once daily, making it possible for many patients to receive systemic treatment at home while being closely monitored by their oncology team.

The Votrient range includes 200 mg and 400 mg film-coated tablets. These strengths can be combined or used individually to build the exact daily dose specified by treatment guidelines and the patient’s individual plan. Generic Meds Mart lists Votrient 200 mg and Votrient 400 mg in practical pack formats – 1 pack / 30 tabs and 1 pack / 60 tabs for the 400 mg strength – which can support one month of once-daily therapy or help match the duration of planned cycles.

As a targeted agent, Votrient pazopanib focuses on signalling pathways that drive tumour blood vessel formation and growth. It does not replace surgery, radiotherapy or other systemic therapies but is integrated into advanced disease strategies where approved. Because pazopanib can affect liver function, blood pressure, heart rhythm and other organ systems, it is prescribed only by clinicians familiar with its safety profile and monitoring requirements.

Generic Meds Mart supplies Votrient pazopanib tablets only in original manufacturer packaging from licensed distributors. Each bottle or blister-style pack carries clear information on strength, tablet count, batch number and expiry date, allowing oncology centres and pharmacies to verify authenticity. Neutral outer packaging protects patient privacy, with no cancer-related wording on the shipping label. Our role is to support access and logistics; treatment decisions remain with your oncology team at all times.

Key Uses

Within the scope of local approvals and guidelines, Votrient pazopanib tablets are commonly used for:

• First-line treatment of advanced or metastatic renal cell carcinoma (RCC) in adult patients who are suitable for oral tyrosine kinase inhibitor therapy.
• Treatment of selected advanced soft tissue sarcomas after prior chemotherapy, depending on sarcoma subtype and regional prescribing information.
• Ongoing disease control in patients with responding or stable disease, as long as benefit continues to outweigh risks and side effects remain manageable.

Your oncology team will decide if Votrient is appropriate for your specific tumour type, stage, prior treatments, comorbidities and personal preferences, and will define the daily dose and expected duration of therapy.

How Pazopanib Works in Chemotherapy

Pazopanib, the active ingredient in Votrient tablets, is a multitargeted tyrosine kinase inhibitor that interferes with several receptors involved in tumour angiogenesis and growth signalling. It potently inhibits vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β) and c-KIT, among other kinases. By blocking these receptors, Votrient pazopanib reduces the development of new blood vessels that tumours need to grow and spread, and can disrupt signalling pathways that support tumour cell survival.

This anti-angiogenic and antiproliferative activity makes pazopanib particularly relevant in cancers such as renal cell carcinoma, which are often highly vascular and rely on VEGF-driven signalling. While Votrient is not a cure for advanced RCC or soft tissue sarcoma, it can help slow disease progression, shrink or stabilise tumours in some patients and potentially prolong progression-free survival when used as part of a well-structured oncology plan.

Dosage & Administration

Votrient pazopanib dosing is determined by oncology specialists and described in local product information. Many adults with advanced RCC start on a target dose equivalent to 800 mg once daily, with dose reductions or adjustments made based on tolerance, liver function, blood pressure and other safety parameters. The 200 mg and 400 mg Votrient tablets are combined to reach the desired total dose, and the choice between 30-tablet and 60-tablet packs supports different refill intervals and clinic schedules.

Votrient tablets should be swallowed whole with water and must not be crushed or broken. They are usually taken on an empty stomach, at least one hour before or two hours after a meal, because food can significantly affect pazopanib absorption. Patients should take the dose at approximately the same time each day and should avoid grapefruit or grapefruit juice unless their oncology team confirms it is safe. If a dose is missed, the patient should follow the instructions from the treatment centre rather than doubling the dose the next day. Any dose changes, temporary interruptions or restarts should always be overseen by the treating oncologist.

Precautions

Because pazopanib can affect multiple organ systems, careful baseline assessment and ongoing monitoring are essential. Liver function tests are checked regularly, and Votrient may be reduced, interrupted or discontinued if significant hepatotoxicity occurs. Blood pressure needs close monitoring, particularly in the first weeks of therapy, as pazopanib can cause or worsen hypertension; antihypertensive medication may be required, and uncontrolled high blood pressure may necessitate treatment modification.

Votrient pazopanib can also prolong the QT interval on ECG and, in rare cases, contribute to serious arrhythmias; patients with known cardiac conditions or those taking other QT-prolonging drugs require especially close supervision. Risk of bleeding, thromboembolic events, gastrointestinal perforation, fistula and impaired wound healing has been described with anti-angiogenic agents, so Votrient use around major surgery must be planned carefully. Drug interactions are possible, particularly with strong CYP3A4 inducers or inhibitors and medications that alter stomach acidity, so a full medication review is vital before starting pazopanib. Votrient is generally avoided during pregnancy and breastfeeding, and reliable contraception is recommended during treatment and for a period after the last dose.

Pazopanib Side Effects

Common side effects

Common pazopanib side effects include diarrhoea, nausea, vomiting, loss of appetite, changes in taste, fatigue, weight loss, hair colour changes, skin discolouration, mild rash, abdominal discomfort and elevated liver enzymes on blood tests. Hypertension is a frequent effect that may require blood pressure tablets. Some patients develop hand–foot skin reactions, mild stomatitis or changes in thyroid function requiring monitoring and, in some cases, replacement therapy.

These side effects are often manageable with supportive care measures, dose adjustments and close communication with the oncology team. Anti-diarrhoeal medications, antiemetics, dietary adjustments, regular hydration and skin care routines can help improve tolerability. It is important not to stop Votrient pazopanib tablets abruptly without consulting the treating team, as they may be able to adjust the dose rather than discontinuing treatment altogether.

Serious side effects

Serious pazopanib adverse effects require urgent medical assessment. These can include signs of severe liver injury (dark urine, severe fatigue, right upper abdominal pain, yellowing of the skin or eyes), severe or sudden-onset hypertension, chest pain, shortness of breath, palpitations, fainting, severe headache, neurological changes, heavy or unusual bleeding, coughing up blood, black tarry stools, severe abdominal pain, signs of gastrointestinal perforation or fistula, or sudden swelling and pain in the limbs that could indicate a clot.

If any of these symptoms occur during treatment with Votrient pazopanib tablets, patients should seek emergency care and inform their oncology team as soon as possible. The medicine may need to be paused or permanently discontinued, and additional investigations and specific treatments may be required.

Storage

Votrient 200 mg and 400 mg pazopanib tablets should be stored in their original bottle or blister at room temperature, usually below 30 °C, protected from moisture and heat. The pack should remain tightly closed when not in use, and tablets should only be removed immediately before dosing to limit exposure to humidity. As with all potent oncology medicines, Votrient must be kept out of the sight and reach of children and stored separately from non-prescription household medicines to avoid accidental ingestion. Unused or expired tablets should be returned to a pharmacy or disposed of according to local cytotoxic or hazardous medicine disposal guidelines.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on structured access to targeted oncology medicines such as Votrient pazopanib tablets. We work exclusively with licensed manufacturers and authorised distributors who comply with Good Manufacturing Practice standards and maintain verifiable batch records. Each Votrient pack supplied is original, sealed and labelled with a batch number and expiry date, supporting verification by your oncology centre or pharmacy.

Listing Votrient pricing in USD and offering both 30-tablet and 60-tablet packs helps patients and clinics plan the cost of multi-month treatment courses. Neutral outer packaging and trackable delivery options (where regulations allow) support privacy and help coordinate supply with clinic visits and monitoring appointments. Our role is strictly limited to sourcing and logistics; we do not replace your oncologist and do not provide individual medical advice about whether Votrient pazopanib is suitable for you.

Order Now

Votrient 200 mg and 400 mg pazopanib tablets are potent targeted therapies for advanced cancers and must only be used according to a detailed plan agreed with an experienced oncology team. Before placing an order, ensure that your diagnosis, previous treatments, current organ function and concomitant medications have been fully reviewed and that your oncologist has specified a pazopanib dose, monitoring schedule and criteria for dose adjustments.

Once this plan is finalised, you or your clinic can calculate how many Votrient 200 mg and Votrient 400 mg packs are required for the upcoming treatment period, taking into account whether 30-tablet or 60-tablet 400 mg packs best match your daily dose and refill schedule. Select the appropriate strengths and pack sizes on Generic Meds Mart, add them to your cart and complete secure checkout in USD. Medicines will be dispatched in discreet packaging. Any new symptoms, concerns or side effects while on Votrient pazopanib must always be discussed promptly with your oncology team rather than managed independently.

FAQ about Votrient (Pazopanib)

Q1: What cancers is Votrient used to treat?
Votrient contains pazopanib, a multikinase tyrosine kinase inhibitor mainly used for advanced or metastatic renal cell carcinoma (RCC) and selected advanced soft tissue sarcomas, in line with local approvals and oncology guidelines.

Q2: Is Votrient chemotherapy or targeted therapy?
Votrient pazopanib tablets are considered a targeted therapy rather than traditional cytotoxic chemotherapy. They work by inhibiting specific tyrosine kinases that drive tumour blood vessel growth and signalling. However, side effects can still be significant, so the medicine is handled with the same level of care as other systemic cancer treatments.

Q3: Do I need to take Votrient with food?
Votrient is usually taken on an empty stomach because food can increase pazopanib levels and change how the medicine is absorbed. Most protocols recommend taking the dose either one hour before or two hours after a meal, at the same time each day, but your oncology team will confirm the exact instructions.

Q4: How long will I stay on Votrient?
The duration of Votrient pazopanib therapy varies between patients. Some remain on treatment as long as scans show disease control and side effects are manageable; others may need dose reductions, temporary breaks or a switch to another therapy. Your oncologist will review your response, tolerability and test results regularly and decide whether to continue, adjust or stop treatment.

Q5: What monitoring will I need while taking Votrient?
Patients on Votrient usually undergo regular blood tests (including liver function and thyroid function), blood pressure checks, ECGs in some cases, and periodic imaging to monitor tumour response. You should also promptly report symptoms such as severe fatigue, jaundice, chest pain, shortness of breath, severe headaches, unusual bleeding or changes in urine or stool colour, as these may indicate important side effects that need urgent attention.

Zotrinib Pazopanib – 400 mg Tablets

At a Glance

Generic Name: Pazopanib

Brand Name: Zotrinib 400 mg

Strength & Pack Size: 400 mg tablets, 1 bottle / 30 tablets

Dosage Form & Route: Oral film-coated tablets for swallowing whole

Therapeutic Class: Multi-targeted tyrosine kinase inhibitor (TKI)

Primary Indications: Advanced or metastatic renal cell carcinoma and selected soft tissue sarcomas, according to local label

Typical Use in Therapy: Continuous daily targeted therapy under oncology supervision, often after or instead of other systemic regimens

Mode of Action: Inhibits VEGFR, PDGFR and related kinases involved in tumour angiogenesis and growth

Key Benefits: Oral once-daily targeted option that can help delay disease progression in appropriately selected patients

Precautions: Requires monitoring of liver function, blood pressure, cardiac status, bleeding risk and drug interactions

Storage: Store in the original bottle below 30 °C, away from moisture and out of reach of children

Product Description

Zotrinib 400 mg contains pazopanib, an oral multi-targeted tyrosine kinase inhibitor used for advanced or metastatic renal cell carcinoma and selected soft tissue sarcomas. As a targeted therapy, Zotrinib 400 mg pazopanib tablets act on specific signalling pathways that tumours use to grow and form new blood vessels. Treatment with pazopanib is always overseen by an experienced oncology team that can assess whether this medicine fits into the overall strategy for controlling advanced disease.

Each bottle of Zotrinib 400 mg supplied by Generic Meds Mart contains 30 film-coated tablets designed to be taken by mouth once daily, at a dose and schedule defined in the official product information and by the treating oncologist. Zotrinib 400 mg is not a generic “chemotherapy pill” that can be started or stopped casually. It is part of a broader management plan that may include earlier surgery, radiotherapy, immunotherapy or other systemic treatments. Before recommending pazopanib, oncologists review tumour type, staging, prior therapies, organ function, comorbidities and potential interactions.

Generic Meds Mart provides Zotrinib 400 mg pazopanib tablets in original oncology packaging from licensed manufacturers and authorised distributors. Bottles are sealed and clearly labelled with strength, batch number and expiry date so that hospital or clinic pharmacies can verify the medicine before dispensing. Outer shipping cartons are neutral and do not mention kidney cancer, soft tissue sarcoma or pazopanib on the outside, which helps protect privacy during international delivery. Prices are displayed in USD to support long-term planning for targeted therapy that may continue for many months if well tolerated and effective.

Key Uses

Within the scope of local approvals and guidelines, Zotrinib 400 mg pazopanib tablets are used in adults with advanced or metastatic renal cell carcinoma and in certain histological subtypes of soft tissue sarcoma after prior chemotherapy. In kidney cancer, pazopanib is typically considered in patients who have unresectable or metastatic disease and are suitable for oral targeted therapy. In soft tissue sarcoma, pazopanib may be used for selected non-adipocytic tumours that have progressed after anthracycline-based regimens, where supported by evidence and regulatory status.

The place of Zotrinib 400 mg in therapy depends on what other agents are available, including tyrosine kinase inhibitors, immunotherapies and combination regimens. Oncologists may recommend pazopanib as a first-line, second-line or later-line treatment based on regional practice and prior responses. Because individual tumours behave differently, ongoing assessment with imaging, symptom review and laboratory monitoring is essential to judge whether Zotrinib 400 mg pazopanib tablets remain beneficial.

How Pazopanib Works in Chemotherapy

Pazopanib, the active ingredient in Zotrinib 400 mg, is a small-molecule tyrosine kinase inhibitor that targets several receptors involved in tumour angiogenesis and proliferation. It inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2 and VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and additional tyrosine kinases such as c-Kit. By blocking these receptors, pazopanib interferes with signalling pathways that promote new blood vessel formation and support tumour survival.

In advanced renal cell carcinoma and soft tissue sarcomas, tumours often rely on angiogenesis to grow and spread. By reducing the formation of new blood vessels and altering pro-growth signalling, Zotrinib 400 mg pazopanib tablets can slow disease progression and, in some cases, shrink measurable lesions. This mechanism is different from traditional cytotoxic chemotherapy that directly damages DNA, but the end goal of controlling tumour burden is similar. Because pazopanib also affects normal vasculature and other tissues, careful monitoring is required to balance potential benefits with risks such as hypertension, bleeding or organ toxicity.

Dosage & Administration

Zotrinib 400 mg pazopanib tablets must only be prescribed and supervised by oncologists familiar with tyrosine kinase inhibitor therapy. The total daily dose is usually expressed in milligrams and composed of one or more 400 mg tablets. Tablets are generally taken once daily, at the same time each day, on an empty stomach or under specific food instructions described in the official pazopanib product information.

Patients are advised to swallow Zotrinib 400 mg tablets whole with water and not to crush, split or chew them. Because pazopanib exposure can be affected by food, antacids, proton pump inhibitors and other medicines, clear written instructions are provided to help standardise dosing conditions. Regular follow-up appointments include physical examination, laboratory tests (particularly liver function), blood pressure measurements and, where indicated, ECG or cardiac imaging. Any dose changes, temporary interruptions or permanent discontinuation of Zotrinib 400 mg are determined by the oncology team based on efficacy and tolerability.

Precautions

Before starting Zotrinib 400 mg pazopanib tablets, oncologists review the patient’s cardiovascular history, liver function, kidney function, bleeding risk, concomitant medicines and potential for drug–drug interactions. Pazopanib has been associated with hepatotoxicity, hypertension, thromboembolic events, haemorrhage, gastrointestinal perforation and, rarely, cardiac dysfunction or QT interval prolongation. Baseline tests and regular monitoring help detect emerging toxicity early.

Patients are usually advised to report symptoms such as severe fatigue, yellowing of the skin or eyes, dark urine, right-sided upper abdominal pain, new or worsening headaches, chest pain, palpitations, shortness of breath, sudden leg swelling, unusual bruising or bleeding, or severe abdominal pain. Pazopanib can interact with medicines that affect CYP3A4 and certain transporters, so all prescription medicines, over-the-counter drugs and herbal supplements should be reviewed before and during therapy. Zotrinib 400 mg pazopanib tablets are generally avoided during pregnancy and breastfeeding, and effective contraception is usually recommended during treatment and for a period afterwards.

Pazopanib Side Effects

Common side effects

Common pazopanib side effects seen with Zotrinib 400 mg include diarrhoea, nausea, vomiting, decreased appetite, changes in taste, fatigue, weight loss, hair colour lightening, skin depigmentation, mild rash, hand–foot skin reactions, hypertension, and mild to moderate liver enzyme elevations. Some patients also experience hypothyroidism, mild proteinuria or transient changes in blood counts.

Many of these common pazopanib side effects can be managed with supportive medicines, dietary adjustments, local skin care, blood pressure control and, when necessary, dose reductions or temporary interruptions. The oncology team will provide guidance on monitoring blood pressure at home, recognising early signs of dehydration and managing diarrhoea. Regular blood tests help identify liver or thyroid changes that may need intervention.

Serious side effects

Serious pazopanib adverse effects require urgent medical attention and may lead to permanent discontinuation of Zotrinib 400 mg. These can include severe hepatotoxicity with marked liver enzyme elevations or jaundice, hypertensive crises, serious bleeding events, venous or arterial thromboembolism, heart failure, QT interval prolongation with arrhythmia, gastrointestinal perforation or fistula, and severe skin reactions.

Patients should seek emergency care if they develop intense right upper abdominal pain, pronounced jaundice, severe headaches with visual disturbances, chest pain, sudden shortness of breath, coughing up blood, one-sided leg swelling, rapid weight gain with swelling, fainting episodes, black or bloody stools or any other alarming symptom. The treating team may need to stop Zotrinib 400 mg pazopanib tablets, address the complication and reassess whether further targeted therapy is appropriate.

Storage

Zotrinib 400 mg pazopanib tablets should be stored in the original bottle with the cap tightly closed, below the temperature specified in the product information, usually not above 30 °C. The bottle should be kept dry, away from direct heat and light, and out of the sight and reach of children. Tablets should not be transferred into unlabelled containers or pill organisers without clear agreement from the treating team, as this may compromise identification and stability. Any tablets remaining after the expiry date should not be used and should be disposed of according to local guidance for cytotoxic or targeted cancer medicines.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to targeted oncology medicines such as Zotrinib 400 mg pazopanib tablets. We work only with licensed manufacturers and authorised distributors that adhere to Good Manufacturing Practice and provide full batch traceability. Each bottle of Zotrinib 400 mg supplied by Generic Meds Mart is delivered in sealed original packaging, so oncology pharmacies can verify brand, strength, batch number and expiry before dispensing.

By listing Zotrinib 400 mg pazopanib tablets in USD, Generic Meds Mart helps patients and clinics plan the cost of long-term targeted therapy more transparently. Neutral shipping cartons protect privacy while still allowing tracked international delivery where regulations permit. Our role is limited to supply and logistics; we do not provide medical advice or replace the treating oncologist. All decisions about starting, continuing, adjusting or stopping Zotrinib 400 mg remain strictly with your oncology team.

Order Now

Zotrinib 400 mg pazopanib tablets are a potent targeted therapy for advanced cancers and must never be used without a detailed treatment plan from an experienced oncologist. Before ordering from Generic Meds Mart, patients and clinicians should confirm the diagnosis, prior treatments, intended pazopanib dose, monitoring schedule and criteria for continuing or adjusting therapy.

Once a plan is agreed, the number of bottles of Zotrinib 400 mg (1 bottle / 30 tablets) required for the initial treatment period can be calculated. You can then select the needed quantity on Generic Meds Mart, add it to your cart and complete secure checkout in USD. Medicines are dispatched in discreet packaging with full original labelling inside. Patients should not change the dose, interrupt therapy or restart Zotrinib 400 mg on their own; any change in treatment or any serious new symptom must be discussed promptly with the oncology team.

FAQ about Zotrinib (Pazopanib)

Q1: What is Zotrinib 400 mg used for?
Zotrinib 400 mg contains pazopanib, a multi-targeted tyrosine kinase inhibitor used under specialist supervision for advanced or metastatic renal cell carcinoma and certain soft tissue sarcomas, in line with local product information and guidelines.

Q2: Is Zotrinib 400 mg chemotherapy or targeted therapy?
Zotrinib 400 mg pazopanib tablets are considered targeted therapy rather than traditional cytotoxic chemotherapy. They block specific kinases involved in tumour angiogenesis and growth. However, they are still powerful anti-cancer medicines with important side effects and monitoring requirements.

Q3: How long will I need to stay on Zotrinib 400 mg?
Duration of Zotrinib 400 mg pazopanib treatment varies. Many patients continue therapy as long as the disease remains controlled and side effects are manageable. Treatment may be changed or stopped if the tumour progresses or toxicity becomes unacceptable. Your oncology team will review scans, symptoms and laboratory results regularly to decide how long to continue pazopanib.

Q4: Can I take other medicines while using Zotrinib 400 mg?
Some medicines and supplements can interact with pazopanib, particularly those affecting CYP3A4 or gastric pH. Always give your oncology team and pharmacist a complete list of prescription drugs, over-the-counter products and herbal remedies before and during therapy. Never start or stop another medicine without checking for interactions with Zotrinib 400 mg.

Q5: What monitoring do I need on Zotrinib 400 mg?
Patients taking Zotrinib 400 mg pazopanib tablets usually need regular liver function tests, blood pressure checks, urine tests, sometimes ECGs and periodic imaging to assess response. These checks help detect side effects such as hepatotoxicity, hypertension, cardiac changes or proteinuria early, so that doses can be adjusted and complications managed promptly.